{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:46Z","timestamp":1793608066816,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anai.2026.02.019","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:16:37Z","timestamp":1772900197000},"page":"699-705.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Donidalorsen for hereditary angioedema"],"prefix":"10.1016","volume":"136","author":[{"given":"Michael E.","family":"Manning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Raasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-3723","authenticated-orcid":false,"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.anai.2026.02.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100792","article-title":"The multifactorial impact of receiving a hereditary angioedema diagnosis","volume":"16","author":"Raasch","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2026.02.019_bib0002","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaip.2023.12.025","article-title":"Clinical progress in hepatic targeting for novel prophylactic therapies in hereditary angioedema","volume":"12","author":"Riedl","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2026.02.019_bib0003","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/jcm10092023","article-title":"The genetics of hereditary angioedema: a review","volume":"10","author":"Santacroce","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.anai.2026.02.019_bib0004","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ced\/llad428","article-title":"Delay in diagnosis is the most important proximate reason for mortality in hereditary angio-oedema: our experience at Chandigarh, India","volume":"49","author":"Kumar Jindal","year":"2024","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.02.019_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0007","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","article-title":"Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region","volume":"153","author":"Honda","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.02.019_bib0008","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.02.019_bib0009","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-023-00795-2","article-title":"A multicenter chart review of patient characteristics, treatment, and outcomes in hereditary angioedema: unmet need for more effective long-term prophylaxis","volume":"19","author":"Mendivil","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2026.02.019_bib0012","doi-asserted-by":"crossref","unstructured":"Villa KF, Mansfield C, Yarlas A, Ruggles JA, Bordone L, Kent C, et al. Patient preferences for long-term prophylactic treatment in hereditary angioedema: a discrete-choice experiment [e-pub ahead of print]. Patient. 2026; doi:10.1007\/s40271-025-00798-8, Accessed February 11, 2026.","DOI":"10.1007\/s40271-025-00798-8"},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0013","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-021-08832-x","article-title":"Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2","volume":"61","author":"Fijen","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"10.1016\/j.anai.2026.02.019_bib0014","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","article-title":"Inhibition of prekallikrein for hereditary angioedema","volume":"386","author":"Fijen","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.02.019_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/nat.2018.0754","article-title":"IONIS-PKK(Rx) a novel antisense inhibitor of prekallikrein and bradykinin production","volume":"29","author":"Ferrone","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.anai.2026.02.019_bib0016","unstructured":"DawnzeraTM (donidalorsen). Full Prescribing Information. Carlsbad, CA: Ionis Pharmaceuticals, Inc; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219407s000lbl.pdf, Accessed August 29, 2025."},{"issue":"1","key":"10.1016\/j.anai.2026.02.019_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.anai.2026.02.019_bib0018","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1111\/all.16563","article-title":"Patient-reported outcomes in the phase III OASIS-HAE study of donidalorsen for hereditary angioedema","volume":"80","author":"Riedl","year":"2025","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2026.02.019_bib0019","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/all.15948","article-title":"A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema","volume":"79","author":"Petersen","year":"2024","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.anai.2026.02.019_bib0020","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the angioedema Quality of Life Questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2026.02.019_bib0021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL): assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.anai.2026.02.019_bib0022","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 Inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.anai.2026.02.019_bib0023","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2026.02.019_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S592079","article-title":"Donidalorsen for long-term prophylaxis of hereditary angioedema attacks: results from the OASISplus open-label extension cohort at year 1","volume":"19","author":"Lumry","year":"2026","journal-title":"J Asthma Allergy"},{"issue":"21","key":"10.1016\/j.anai.2026.02.019_bib0025","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1523\/JNEUROSCI.2087-20.2021","article-title":"Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1","volume":"41","author":"Yang","year":"2021","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.anai.2026.02.019_bib0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jaip.2014.11.012","article-title":"Clinical features of pediatric hereditary angioedema","volume":"3","author":"Nanda","year":"2015","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626000955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:42:30Z","timestamp":1793605350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1081120626000955"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.019","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donidalorsen for hereditary angioedema","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}